Toripalimab（JS001） as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors

Inclusion Criteria: * Participants must provide written informed consent to participate * Adult aged between 18 and 75 years old * Participants with Histologically- or cytologically- proven advanced solid tumors and not responding to standard therapy * MSS (microsatellite sability) or MSI-L (microsatellite instability-low) or pMMR status * Germline mutations or somatic mutations in POLE or POLD (synonymous mutation is excluded) * Patients refuse any conventional chemotherapy or targeted therapy * Patients are willing to take biopsy of tumor tissue and take blood samples before treatment (blood samples are also taken at each time of therapeutic evaluation) * Participants must have at least one measurable site of disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Lesions previously treated with radiotherapy should not be regarded as target lesions unless there is a definite progression of the lesion after radiotherapy. * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Estimated life expectancy is greater than 3 months * Participants can provide more than 10 paraffin sections of tumor tissue * No history of radiotherapy or received non-targeted radiotherapy outside the target lesions for this study more than 4 weeks ago before the first dose of study treatment * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x (5 x in participants with liver metastasis) upper limit of normal (ULN) * Albumin ≥ 3 g…